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 Alcoholic hepatitis is a leading cause of liver failure in which the increased production of tumor 
necrosis factor α (TNFα) plays a critical role in progression of alcoholic liver disease. In the present 
study, we investigated the effects of cilostazol, a selective inhibitor of type III phosphodiesterase on 
ethanol-mediated TNFα production  in vitro and in vivo, and the effect of cilostazol was compared 
with that of pentoxifylline, which is currently used in clinical trial. RAW264.7 murine macrophages 
were pretreated with ethanol in the presence or absence of cilostazol then, stimulated with lipo-
polysacchride (LPS). Cilostazol significantly suppressed the level of LPS-stimulated TNFα mRNA and 
protein with a similar degree to that by pentoxifylline. Cilostazol increased the basal AMP- activated 
p r o te i n ki nase  ( AMP K)  ac ti vi ty as w e ll as no r mali ze d  the  d e c r e ase d  AMP K b y LP S. AICAR, an AMP K  
activator and db-cAMP also significantly decreased TNFα production in RAW264.7 cells, but cilostazol 
did not affect the levels of intracellular cAMP and reactive oxygen species (ROS) production. The in 
vivo e f f e c t o f  c i lo stazo l was e xami ned  usi ng e thano l b i nge d r i nki ng ( 6 g/kg)  mi c e  mo d e l. TNFα mRNA 
and protein decreased in liver from ethanol gavaged mice compared to that from control mice. Pre-
treatment of mice with cilostazol or pentoxifylline further reduced the TNFα production in liver. These 
results demonstrated that cilostazol effectively decrease the ethanol-mediated TNFα production both 
in murine macrophage and in liver from binge drinking mice and AMPK may be responsible for the 
inhibition of TNFα production by cilostazol. 
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INTRODUCTION
  Alcohol consumption is one of the major causes of liver 
disease, which is a spectrum including simple alcoholic 
steatosis, alcoholic hepatitis and cirrhosis. Severe alcoholic 
hepatitis can be life-threatening and a common reason for 
hospitalization after heavy alcohol drinking. The progres-
sion of alcoholic liver diseases is regulated by various fac-
tors and the increased levels of pro-inflammatory factors 
are known to be important contributors. Heavy alcohol in-
take causes increase of endotoxin/lipopolysaccharide (LPS) 
in the blood, which in turn activates Kupffer cells, the resi-
dent hepatic macrophage, leading to the increased produc-
tion of several proinflammatory cytokines, such as TNFα 
and interleukin-6. In particular, TNFα has been shown to 
play a critical role in the progression of alcoholic liver dis-
ease [1,2]. Previous animal studies have shown that rats 
treated with TNFα antibody and TNFα receptor I knock-
out mice are resistant to alcohol-induced liver injury [3,4]. 
In addition, the treatment of antibiotics which reduce the 
level of blood endotoxin prevents the hepatic steatosis and 
inflammation in rats after exposure to alcohol [5]. 
  A significant amount of studies, therefore, have focused 
on the regulation of TNFα production in liver exposed to 
alcohol to develop effective therapies for alcoholic hepatitis. 
The expression of TNFα in LPS-stimulated Kupffer cell is 
regulated by a number of signal molecules, including re-
active oxygen species (ROS) and cAMP [6,7]. Among the 
regulators of TNFα expression, it has been clearly demon-
strated that the elevation of cyclic AMP (cAMP) suppresses 
the expression of TNFα in macrophage [8,9]. In consistent 
with these observations, phosphodiesterase (PDE) inhibi-
tors suppressed TNFα production in macrophage through 
elevating intracellular cAMP [10-12]. 132 YJ Lee and JR Eun
  In recent years, pentoxifylline, a non-selective PDE in-
hibitor has attracted interest in clinical trials and has been 
pointed as a preferred first-line agent for treatment of alco-
holic hepatitis due to its safety compared to glucocorticoids 
[13]. However, the studies on its efficacy are limited and 
its effects are unclear in some clinical situations [14]. At 
this time, no other therapeutic modalities for severe alco-
holic hepatitis are available. Therefore, more studies on 
pentoxifylline are needed as well as new pharmacological 
therapy is urgent. 
  Cilostazol is a selective PDE3 inhibitor, which is known 
to inhibit platelet aggregation by increase of intracellular 
cAMP. Thus, cilostazol is widely used for treatment of pe-
ripheral vascular diseases [15,16]. In addition to its anti-
platelet effect, recent studies have suggested its various 
pharmacologic effects including anti-inflammatory, anti-
oxidant and anti-apoptotic effects via cAMP-dependent and 
-independent pathways [17-19]. Cilostazol has also shown 
a beneficial effect on liver steatosis in non-alcoholic fatty 
liver disease animal model [20]. 
  In the present study, we have examined the effects of 
cilostazol on ethanol-mediated TNFα expression in in vitro 
and in vivo model using RAW264.7 murine macrophage and 
binge drinking mice and the effect of cilostazol was com-
pared to that of pentoxifylline. 
METHODS 
Materials
    Cilostazol was donated by Otsuka Pharmaceuticals 
(Tokushima, Japan). Dulbecco’s modified eagle’s medium 
(DMEM), fetal bovine serum (FBS) and penicillin/strepto-
mycin, and 5-(and-6)-carboxy-2’,7’-dichlorodihydrofluores-
cein diacetate (carboxy-H2DCFDA) were purchased from 
Invitrogen (Carlsbad, CA, USA). LPS (Escherichia coli 
0111:B4), db-cAMP, 5-Aminoimidazole-4-carboxamide 1-β- 
D-ribofuranoside (AICAR), pentoxifylline, ethanol, carbox-
ymethylcellulose, 3-(4,5-dimethylthiazole-2yl)-2,5-diphenyl- 
2H-tetrazolium bromide (MTT) and protease inhibitors 
(aprotinin, leupentin, pepstatin A) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). The phospho-AMPK 
antibody was from Cell Signaling Technology (Beverly, MA) 
and GAPDH antibody was from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA).
Cell culture and treatment 
  The RAW264.7 murine macrophage was obtained from 
the Korean Cell Line bank (Seoul, Korea) and cultured in 
DMEM containing 10% FBS, 100 U/ml penicillin, 100 μg/ 
ml streptomycin and maintained at 37
oC in a humidified 
incubator with 5% CO2 atmosphere. For experiments, cells 
were plated at a density of 1×10
5/cm
2 and treated with 25 
mM ethanol for 24 h in the presence or absence of cilostazol 
and pentoxifylline [21,22]. Then, cells were stimulated with 
50 ng/ml LPS. 
Ethanol binge
  Seven-week old male C57BL/6 (18∼22 g) mice were ob-
tained from Central Lab. Animal Inc. (Seoul, Korea). Mice 
were housed in a specific pathogen-free animal care facility 
under a 12 h light/dark cycle and were allowed to free ac-
cess to standard laboratory chow and tab water. Ethanol 
binge model developed by Carson and Pruett [23] was used. 
After one week acclimatization, mice were divided into sev-
en groups: control, ethanol (6 g/kg body weight, p.o.), cil-
ostazol (100 mg/kg/day, i.p.), cilostazol (50 and 100 mg/ 
kg/day, i.p.)＋ethanol, pentoxifylline (50 and 100 mg/kg/ 
day, i.p.)＋ethanol. Mice were administered cilostazol, pen-
toxifylline, or vehicle (0.5% carboxyl methylcellulose) for 4 
days before ethanol administration. Ethanol was diluted 
with sterile water (32% w/v) and was given orally 1 h after 
the last treatment with cilostazol or pentoxifylline. Mice 
were sacrificed 6 h after ethanol administration and liver 
was collected. The doses of cilostazol or pentoxifylline used 
in this study were selected by following previous studies 
reported by others [20,24-26]. The protocol for animal care 
and use was approved by Animal Care and Use Committee 
of Yeungnam University. 
Cell viability
  Cell viability was measured based on the conversion of 
water soluble tetrazolium MTT to water-insoluble blue for-
mazan by viable cells. Cells were treated with various con-
centrations of cilostazol or pentoxifylline in the presence 
or absence of 25 mM ethanol for 24 and 48 h. Then, cells 
were treated with MTT (5 mg/ml in PBS) and incubated 
for 4 h. The formation of formazan was dissolved in DMSO 
and the optical density was measured at 570/620 nm. 
Protein extracts 
  Cells were lysed on ice in lysis buffer (20 mM HEPES 
(pH 7.5), 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 2 mM 
MgCl2, 150 mM NaCl, 10 mM KCl, 1% NP-40, 1 mM 
Na3VO4, 1 mM DTT, 1 mM benzamide, 1 mM PMSF, and 
protease inhibitors). Liver was homogenized in lysis buffer 
supplemented with 1% glycerol. After centrifugation at 
13,000 g, the supernatant was taken and protein concen-
tration was determined by Bradford reagent (Sigma, St. 
Louis, MO). 
Enzyme-linked immunosorbent assay (ELISA) of TNFα
  The levels of TNFalpha in cell and liver were determined 
using mouse TNFα ELISA kit (R&D Systems, Inc., Min-
neapolis, MN). One hundred microliter of cell culture media 
or liver extract was used and the assay was performed ac-
cording to protocol provided by manufacturer. The amount 
of TNFα production was expressed as pg/mg protein.
Semiquantative- and real time RT-PCR
  Total RNA was extracted from RAW264.7 macrophage or 
liver using Tri reagent (Sigma, St. Louis, MO). RNA was 
reverse transcribed to cDNA from 1 μg of total RNA using 
a High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA). For semiquantitative 
PCR, the following primers were used: TNFα (307 bp: for-
ward, 5'-GGCAGG-TCTACTTTGGAGTCATTGC-3'; rever-
se, 5'-ACATTCGAGGCTCCAGTGAATTCGG-3’); 18s rRNA 
(209 bp: forward, 5'-CCCGGGGAGGTAGTGACGAAAAAT- 
3'; reverse 5'-CGCCCGCTCCCAAGATCCAACTAC-3'). Quanti-
tative real-time PCR was performed using the Real-Time 
PCR 7500 system and Power SYBR Green PCR master mix 
(Applied Biosystems) according to the manufacturer’s Cilostazol Decreases Ethanol-mediated TNFα 133
Fig. 1. The effects of cilostazol and 
pentoxifylline on viability of RAW264.7
cells. Cells were pretreated with cilo-
stazol (0∼100 μM) or pentoxifylline 
(100 μM) for 1 h followed by treat-
ment with 25 mM ethanol or vehicle 
control (culture media) for 24 h (A) 
and 48 h (B). Data represented as 
percentage of cell survival over the 
control cells are mean±SEM of four 
independent experiments. *p＜0.05 
vs. control (CTZ, cilostazol; PTX, 
pentoxifylline; EtOH, ethanol).
Fig. 2. The effects of cilostazol and pentoxifylline on LPS-stimu-
lated TNFα expression in RAW264.7 cells exposed to ethanol. Cells 
were treated with 25 mM ethanol in presence of cilostazol (50 and 
100 μM), pentoxifylline (100 μM) or DMSO (vehicle control) for 
24 h. Then, cells were stimulated with 50 ng/ml LPS for 4 h. (A) 
The accumulation of TNFα in cell culture media was measured 
by ELISA and normalized by the amount of protein of each sample. 
Data represented as percentage of TNFα production over DMSO 
group are mean±SEM of four independent experiments. (B) The 
level of TNFα mRNA was measured by RT-PCR. *p＜0.05 vs. 
DMSO group (CTZ, cilostazol; PTX, pentoxifylline).
instructions. The thermal cycling conditions were initial in-
cubation at 95
oC for 10 minutes, followed by 45 cycles of 
95
oC for 15 seconds, 55
oC for 20 seconds, and 72
oC for 35 
seconds. Primers for mouse TNFα (71 bp: forward, 5'- 
CTATCTCCAGGTTCTCTTCAA-3'; reverse, 5'-GCAGAG-
AGGAGGTTGACTTTC) and β-actin (121 bp: forward, 5'- 
TGGACAG-TGAGGCAAGGATAG-3'; reverse, 5'-TACTG-
CCCTGGCTCCTAGCA-3') were designed using the Primer 
Express program (Applied Biosystem). The expression level 
of β-actin was used as an internal control. 
Reactive oxygen species (ROS) measurement
  To determine ROS generation, FACS analysis was per-
formed. Cells were incubated with 50 μM carboxy- 
H2DCFDA (Invitrogen, Carlasbad, CA) for 40 min. Cells 
were washed with PBS and subjected to flow cytometry us-
ing a Becton-Dickinson FACS Caliber and analyzed by Cell 
Quest software (Becton-Dickinson, San Jose, CA). 
Intracellular cAMP measurement
  The concentration of cAMP was measured using cAMP 
EIA kit (Cayman, Ann Arbor, MI) according to the manu-
facturer’s protocols. Briefly, cells were lysed in 1 ml of lysis 
buffer and 50 μl of supernatant after centrifugation was 
used for assay and then the absorbance was measured at 
405 nm. 
Western blotting 
  Equal amounts of proteins from cell lysates were sepa-
rated by 10% SDS-PAGE gel and transferred to nitro-
cellulose membrane (Bio-Rad, Hercules, CA). The mem-
brane was blocked with 5% non-fat dry milk in Tris- buf-
fered saline. The blots were incubated with primary anti-
body for phospho-AMPK (Cell signaling, Beverly, MA) and 
then, reacted with a peroxidase-conjugated secondary anti-
body. The protein bands were detected using an enhanced 
chemiluminescence detection system (Millipore, Billerica, 
MA). The density of respective bands was analyzed by the 
LAS-3000 imaging system (Fuji film, Tokyo, Japan). The 
membrane was reprobed with anti-GAPDH antibody, which 
was used as loading control.
Statistics 
  Data are expressed as means±SEM. Statistical analyses 
were  made b y the  Student’s t-test to compare values be-
tween two groups or by one way ANOVA followed by 
Tukey’s post hoc test to compare values among more than 
three groups. A value of p＜0.05 was considered significant.134 YJ Lee and JR Eun
Fig. 3. The effects of cilostazol and pentoxifylline on LPS-induced 
ROS production in RAW264.7 cells exposed to ethanol. Cells were 
treated with 25 mM ethanol in presence of cilostazol (100 μM), 
pentoxifylline (100 μM) or DMSO for 24 h. Then, cells were 
stimulated with 50 ng/ml LPS for 4 h. After incubation of cells with 
50 μM carboxy-H2DCFDA for 40 min, the production of ROS was 
measured by flow cytometry. Data represented as percentage 
increases over the DMSO control and are expressed as mean±SEM
of three independent experiments. *p＜0.05, **p＜0.01 vs. control. 
#p＜0.05 vs. corresponding DMSO-treated cells (Con, control; CTZ, 
cilostazol; PTX, pentoxifylline).
RESULTS
The effects of cilostazol on LPS-stimulated TNFα 
production in RAW264.7 macrophage exposed to 
ethanol 
  We first examined the cytotoxic effects of cilostazol and 
pentoxifylline on RAW264.7 cells after ethanol exposure. 
The treatment of cells with cilostazol (0∼100 μM) or pen-
toxifylline (100 μM) for 24 h did not cause cytotoxicity at 
any concentration used regardless of the presence of 
ethanol. At 48 h, pentoxifylline reduced cell viability ∼8% 
and ethanol did not have any effects on cell viability (Fig. 
1). In the subsequent experiments, cells were treated with 
cilostazol or pentixifylline for 24 h.
  Next, the effect of cilostazol on LPS-stimulated TNFα 
expression in the presence of 25 mM ethanol was deter-
mined. LPS increased about 260 fold (∼29 ng/mg protein) 
of TNFα production in culture media, which was sig-
nificantly reduced to 56%, 65% and 76% by pretreatment 
with 100 μM cilostazol, 50 μM cilostazol and 100 μM pen-
toxifylline, respectively, compared to DMSO, a vehicle con-
trol (Fig. 2A). The level of TNFα mRNA was also sub-
stantially reduced by cilostazol and pentoxifylline, showing 
similar results to that of ELISA (Fig. 2B). These results 
indicate that cilostazol reduces LPS-stimulated TNFα pro-
duction in RAW 264.7 cells exposed to ethanol in dose-de-
pendent manner and the degree of its inhibition is com-
parable to that by pentoxifylline. 
The  r o l e  o f  ROS, c AMP a nd AMPK i n the  i nhi bi ti o n  
of TNFα production by cilostazol
 Since ROS has been shown to be an important contributor 
to LPS-stimulated TNFα production in macrophage [7,27], 
the effect of cilostazol on ROS production in RAW264.7 
macrophage was examined to elucidate the underlying 
mechanisms. The production of ROS was increased about 
2 fold by LPS treatment for 4 h (Fig. 3). However, the in-
crease was not ameliorated by pretreatment with cilostazol 
or pentoxylline. This result indicates that suppression of 
ROS production is not involved in the action of cilostazol 
or pentoxifylline. Next, the role of cAMP in the action of 
cilostazol was examined. As shown in Fig. 4A, pretreatment 
with db-cAMP, a cell-permeable cAMP analog significantly 
reduced LPS-stimulated TNFα production by 39%. Howev-
er, the intracellular cAMP was not changed by cilostazol 
or pentoxifylline (Fig. 4B), indicating that the inhibition of 
TNFα by cilostazol occurs via cAMP-independent pathway.
  Recent studies have shown the regulation of TNFα ex-
pression by AMP-activated protein kinase (AMPK) [28,29]. 
We therefore examined whether the inhibition of LPS- 
stimulated TNFα production by cilostazol in macrophage 
exposed to ethanol was attributable to activation of AMPK. 
The cells were treated with LPS (50 ng/ml) for different 
time (0∼4 h) and the activation of AMPK was measured 
by Western blotting. The treatment with LPS decreased 
AMPK activation about 60% at 30 min (Fig. 4C). In con-
trast, cilostazol treatment (0∼4 h) increased AMPK activa-
tion about 2 fold within 5 min and then gradually returned 
to basal. A pharmacological activator of AMPK, AICAR in-
creased AMPK activation about 30%. The pretreatment 
with cilostazol increased basal AMPK activity about 2- fold 
and normalized the level of AMPK activation in LPS-stimu-
lated RAW264.7 cells, whereas pentoxifyllin did not affect 
the activation of AMPK (Fig. 4D). Consistent with this re-
sult, AICAR reduced LPS-stimulated TNFα production in 
RAW264.7 cells exposed to ethanol (Fig. 4A). These results 
indicate that AMPK but not cAMP is involved in the in-
hibition of TNFα production by cilostazol in RAW264.7 
cells. 
The inhibition of TNFα expression by cilostazol in 
binge drinking mice 
  The effects of cilostazol on TNFα production by ethanol 
was examined in in vivo animal model. Acute ethanol ex-
posure to mice by gavage at a single dose 6 g/kg body weight 
has shown to significantly increase TNFα production with 
maximum increase at 6 h after ethanol administration 
[30,31]. The same protocol was followed in the present 
study for development of binge drinking model. The levels 
of TNFα mRNA and protein in liver after ethanol admin-
istration were determined by real-time PCR and ELISA, 
respectively. Unexpectedly, the level of TNFα mRNA was 
decreased at 6 h after ethanol treatment by 25~30%. The 
pretreatment with cilostazol (50 and 100 mg/kg) and pen-
toxifylline (50 and 100 mg/kg) further reduced the TNFα 
mRNA, although cilostazol itself did not change the level 
of TNFα expression (Fig. 5A). The ELISA assay also shows 
similar results (Fig. 5B). These results indicate that cil-
ostazol decreases the expression of TNFα mRNA and pro-
tein in liver after ethanol exposure in vivo with similar ex-
tent to pentoxifylline, although ethanol treatment reduced 
the level of TNFα in this model. 
DISCUSSION
  The results from this study have shown that cilostazol 
significantly suppressed LPS-stimulated TNFα production 
in RAW 264.7 murine macrophage exposed to ethanol and Cilostazol Decreases Ethanol-mediated TNFα 135
Fig. 4. The role of cAMP and AMPK in the effects of cilostazol on inhibition of TNFα production in RAW264.7 cells. (A) Cells were 
treated with 25 mM ethanol in presence of cilostazol (100 μM), db-cAMP (100 μM), AICAR (1 mM) or DMSO for 24 h and then, stimulated
with 50 ng/ml LPS for 4 h. The level of TNFα production from cell culture media was measured by ELISA and normalized by the amount 
of protein of each sample. Data are represented as percentage of TNFα production over LPS-stimulated cells in vehicle control (DMSO) 
group and are expressed as mean±SEM of three independent experiments. (B) Cells were treated with cilostazol, pentoxifylline and db-cAMP 
for 15 min, and then intracellular cAMP was measured. The concentrations of cAMP (pmol/ml) are represented as fold increase over the 
control and are expressed as mean±SEM of three independent experiments. (C) Cells were treated with 50 ng/ml LPS or 100 μM cilostazol
for different time (0∼4 h) and 1 mM AICAR for 1 h, or (D) cells were treated with 50 ng/ml LPS in the presence or absence of cilostazol 
(100 μM) or pentoxifylline (100 μM) for 30 min. Whole cell extracts were prepared and the activation of AMPK was detected by Western 
blotting. The blots are representative of three independent experiments. *p＜0.05, **p＜0.01 vs. DMSO control group (CTZ, cilostazol; PTX,
pentoxifylline).
in liver from binge drinking mice. 
  Numerous clinical and experimental studies have shown 
that the increased level of hepatic TNFα and monocyte 
TNFα production in alcoholic hepatitis are positively corre-
lated with disease severity [2,32]. Chronic ethanol exposure 
enhances LPS-stimulated TNF production in RAW264.7 
cells as well as Kupffer cells [21,22]. In accordance with 
this observation, inhibition of TNFα by TNFα antibody 
reduced liver injury in alcohol fed rats [3]. Recent clinical 
reports have provided beneficial effects of pentoxifylline, a 
TNFα suppressor for treatment of alcoholic hepatitis and 
have suggested this treatment as an alternative to gluco-
corticoids [13]. At this time, however, its efficacy on surviv-
al benefit is controversial [14,33]. It is necessary to conduct 
more studies on the effects of pentoxifylline while the devel-
opment of new pharmacological therapy for alcoholic hep-
atitis is needed. Our results show that cilostazol sig-
nificantly suppresses LPS-stimulated TNFα production in 
ethanol-primed RAW264.7 as well as binge drinking mice 
and the extent of inhibition by cilostazol is comparable to 
that of pentoxifylline. The overproduction of TNFα by 
ethanol has been shown to be associated with increased 136 YJ Lee and JR Eun
TNF mRNA expression [22,34]. In agreement with these 
results, the level of TNFα mRNA was increased by ethanol 
and LPS in RAW264.7 cells, which was decreased by cil-
ostazol and pentoxifylline. These data suggest that both cil-
ostazol and pentoxifylline suppress the production of 
TNFalpha at transcription level. 
  The underlying mechanisms by which ethanol increases 
TNFα expression in macrophage have been extensively 
studied. LPS increases ROS production in Kupffer cells and 
ethanol exposure further increase LPS-induced ROS pro-
duction, which leads to increase of TNFα production [7]. 
We have also observed that LPS simulation increases ROS 
production in RAW264.7 cells exposed to ethanol. However, 
neither cilostazol nor pentoxifylline reduced LPS-stimu-
lated ROS production. This indicates that the inhibition of 
TNFα production by cilostazol occurs via ROS-independent 
pathway. Although previous study has shown that cil-
ostazol attenuates NADPH oxidase-derived ROS production 
in macrophage [35], intracellular ROS can be generated 
from various sources including NADPH oxidase and mi-
tochondrial electron transport chain [36]. A lot of studies 
have shown that mitochondria plays a critical role in etha-
nol-induced ROS production and liver injury [37,38]. Fur-
thermore, Chandel et al. [27], have shown that antioxidants 
had no effect on LPS-induced TNFα expression in murine 
macrophage. 
  Enhanced intracellular cAMP has been well known to sup-
press LPS-stimulated TNFα production in macrophage in 
vivo and in vitro [39,40]. Moreover, chronic ethanol ex-
posure results in decrease of cAMP, which is one of mecha-
nisms responsible for increased TNFα production from 
Kupffer cells and macrophages [21,22]. Concomitant with 
these observations, previous studies have documented that 
various cAMP elevating agents including adenylyl cyclase 
activator and PDE inhibitors invariably suppress TNFα 
production in macrophages. Our data also shows that db-cAMP 
significantly reduced TNFα production in RAW264.7 cells, 
supporting previous reports by others. However, cilostazol 
and pentoxifylline did not increase intracellular cAMP lev-
els in the present study, indicating that cilostazol inhibition 
of TNFα production in ethanol treated macrophage is 
cAMP-independent. Similarly, previous studies have also 
shown that cilostazol did not change intracellular cAMP in 
RAW264.7 macrophage [19,24]. 
 The activation of AMPK has been shown to repress in-
flammatory responses stimulated with LPS in vitro and in 
vivo [28,29]. Recent studies have shown that the anti-in-
flammatory effects of cilostazol in vascular smooth muscle 
cells and endothelial cells occur by activation of AMPK 
pathway which is independent of cAMP [28,29]. Our data 
support this findings demonstrating that AICAR, an activa-
tor of AMPK suppressed ethanol-mediated TNFα produc-
tion and cilostazol enhanced LPS decreased AMPK activa-
tion in RAW264.7 cells exposed to ethanol. These results 
suggest that cilostazol exerts the inhibitory effects on TNFα 
production in ethanol-primed RAW264.7 cells through acti-
vation of AMPK. 
 Various alcohol binge animal models have been employed 
to study alcoholic hepatitis [41,42]. In preliminary experi-
ments, we observed significant increase in serum ALT/AST, 
Fig. 5. The effects of cilostazol and pentoxifylline on TNFα expres-
sion in liver from binge drinking mice. Mice were treated with 
cilostazol (50 and 100 mg/kg) or pentoxifyline (50 and 100 mg/kg) 
for 4 days by intraperitoneal injection and control mice were 
treated with vehicle (0.5% carboxyl methylcellulose). Then, mice 
were intragastrically administered with 6 g/kg ethanol and sa-
crificed 6 h after ethanol administration. Liver was collected to 
measure TNFα mRNA (A) and protein (B) by real-time PCR and 
ELISA, respectively. Data are represented as mean±SEM (n=5∼6 
mice). *p＜0.05 vs. control group (CTZ, cilostazol; PTX, pentoxi-
fylline; EtOH, ethanol). Cilostazol Decreases Ethanol-mediated TNFα 137
makers of liver injury and hepatic TNFα mRNA expression 
6 h after gavage of a single dose of 6 g/kg or three doses 
of 5 g/kg ethanol, similar results to previous reports by oth-
ers [31,42]. In subsequent repeated experiments, however, 
we obtained the opposite results that TNFα expression 
was rather decreased in mice gavaged with 6 g/kg ethanol 
compared with that in control mice. Recent study has 
shown similar finding that the administration of either a 
single dose or three dose of ethanol (5 g/kg) to rats sup-
pressed TNFα expression in liver collected 4 h after etha-
nol gavage [41]. Several previous studies have demon-
strated that binge ethanol causes dual effects, pro- and an-
ti-inflammatory responses; mostly anti-inflammatory ef-
fects at early after ethanol treatment (0∼6 hr) and pro-in-
flammatory effects later after ethanol treatment (after 24 
hr) [43,44]. In addition, the differential effects of binge alco-
hol drinking on hepatic TNFα production in animal model 
may be due to different animal species and different animal 
batches used in experiments. Although we failed to present 
the increase of hepatic TNFα expression by ethanol binge 
itself, our data clearly show that cilostazol does decrease 
the expression of TNFα in liver exposed to ethanol in vivo 
and the degree of inhibition by cilostazol is similar to that 
by pentoxifylline. However, additional studies to examine 
the effect of cilostazol on the TNFα production in ethanol- 
fed animal model are needed to make concrete conclusion. 
  Taken together, these data demonstrate that cilostazol 
suppresses ethanol-mediated TNFα expression in RAW264.7 
macrophage and in liver from binge drinking mice and the 
effects of cilostazol involves AMPK activation. Furthermore, 
the effects of cilostazol are comparable to that of pentoxi-
fylline. 
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